The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease Academic Article Article uri icon

Overview

MeSH Major

  • Epigenesis, Genetic
  • Inflammatory Bowel Diseases
  • Stress, Physiological

abstract

  • Tegaserod in a dose of 1 mg/day causes a significant decrease in postprandial oesophageal acid exposure. The reduction in oesophageal acid exposure with tegaserod treatment may result from enhanced oesophageal acid clearance, improved gastric emptying, and/or reduced transient lower oesophageal sphincter relaxations.

publication date

  • December 4, 2000

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1046/j.1365-2036.2000.00854.x

PubMed ID

  • 11069322

Additional Document Info

start page

  • 1503

end page

  • 9

volume

  • 14

number

  • 11